scholarly journals The Screening Test for Aphasia and Dysarthria (STAD) for patients with neurological communicative disorders: a large-scale, multicenter validation study in Japan

2021 ◽  
Author(s):  
Kentaro Araki ◽  
Yoshiyuki Hirano ◽  
Machiko Kozono ◽  
Junko Fujitani ◽  
Eiji Shimizu
Keyword(s):  
Validation Study ◽  
Screening Test ◽  
Large Scale ◽  
Communicative Disorders ◽  
Multicenter Validation

Multicenter validation study of two blockcycler- and one capillary-based real-time PCR methods for the detection of Salmonella in milk powder

2007 ◽  
Vol 117 (2) ◽  
pp. 211-218 ◽  
Author(s):  
Burkhard Malorny ◽  
Dietrich Mäde ◽  
Paul Teufel ◽  
Cornelia Berghof-Jäger ◽  
Ingrid Huber ◽  
...  
Keyword(s):  
Real Time ◽  
Validation Study ◽  
Real Time Pcr ◽  
Milk Powder ◽  
Multicenter Validation

scholarly journals Large-scale validation of SCIAMACHY reflectance in the ultraviolet

2005 ◽  
Vol 5 (2) ◽  
pp. 1771-1796 ◽  
Author(s):  
G. van Soest ◽  
L. G. Tilstra ◽  
P. Stammes
Keyword(s):  
Radiative Transfer ◽  
Validation Study ◽  
Large Scale ◽  
Scale Validation ◽  
Radiative Transfer Model ◽  
Transfer Model ◽  
Time Level ◽  
Standard Calibration ◽  
Level 1 ◽  
Reflectance Data

Abstract. In this paper we present an extensive validation of calibrated SCIAMACHY nadir reflectance in the UV (240–400 nm) by comparison with spectra calculated with a fast radiative transfer model. We use operationally delivered near-real-time level 1 data, processed with 5 standard calibration tools. A total of 9 months of data has been analysed. This is the first reflectance validation study incorporating such a large amount of data. It is shown that this method is a valuable tool for spotting spatial and temporal anomalies. We conclude that SCIAMACHY reflectance data in this wavelength range are stable over the investigated period. In addition, we show an example of an 10 anomaly in the data due to an error in the processing chain that could be detected by our comparison. This validation method could be extremely useful too for validation of other satellite spectrometers, such as OMI and GOME-2.

scholarly journals Detecting central sleep apnea in adult patients using WatchPAT—a multicenter validation study

2019 ◽  
Vol 24 (1) ◽  
pp. 387-398 ◽  
Author(s):  
Giora Pillar ◽  
Murray Berall ◽  
Richard Berry ◽  
Tamar Etzioni ◽  
Noam Shrater ◽  
...  
Keyword(s):  
Sleep Apnea ◽  
Validation Study ◽  
Central Sleep Apnea ◽  
Adult Patients ◽  
Multicenter Validation

scholarly journals “Very early” intrahepatic cholangiocarcinoma may become an acceptable indication for liver transplantation. A multicenter validation study

HPB ◽  
2016 ◽  
Vol 18 ◽  
pp. e46-e47
Author(s):  
G. Sapisochin ◽  
M. Facciuto ◽  
N. Mehta ◽  
E. Vibert ◽  
R. Hernandez-Alejandro ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Intrahepatic Cholangiocarcinoma ◽  
Validation Study ◽  
Multicenter Validation

Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories

2020 ◽  
pp. 520-533 ◽  
Author(s):  
Natasha B. Leighl ◽  
Suzanne Kamel-Reid ◽  
Parneet K. Cheema ◽  
Janessa Laskin ◽  
Aly Karsan ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Validation Study ◽  
Growth Factor Receptor ◽  
Clinical Laboratories ◽  
Epidermal Growth ◽  
Positive Results ◽  
Egfr T790m ◽  
Multicenter Validation

PURPOSE Plasma detection of EGFR T790M mutations is an emerging alternative to tumor rebiopsy in acquired epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor resistance. Validation of analytical sensitivity and clinical utility is required before routine diagnostic use in clinical laboratories. PATIENTS AND METHODS Sixty-three patients with advanced EGFR-mutant lung cancer at 7 Canadian centers, who were being screened for the ASTRIS trial (ClinicalTrials.gov identifier: NCT02474355 ), participated in this companion study. Plasma T790M mutation was detected using droplet digital polymerase chain reaction, Cobas (Roche Diagnostics, Indianapolis, IN), or next-generation sequencing in 4 laboratories. T790M concordance was assessed between plasma and tumor samples. RESULTS Assessment of T790M in tumor biopsy tissue was successful in 81% of patients; 49% had confirmed T790M results (tumor or plasma) for ASTRIS. Plasma testing in this companion study yielded T790M results in 97% of patients; 62% had T790M-positive results, 36% had negative results, and 2% had indeterminate results. Of 38 patients with negative or indeterminate biopsy results, 55% had positive plasma T790M results, increasing the proportion with T790M-positive results to 73%. Sensitivity of plasma T790M testing was 75%. Overall concordance between tissue and plasma was 64%, and concordance among laboratories was 90.3%. Response to osimertinib and duration of therapy were similar irrespective of testing method (overall response rate, 62.5% for tissue, 66.7% for plasma, and 70.6% for both). CONCLUSION This multicenter validation study demonstrates that plasma EGFR T790M testing can identify significantly more patients than biopsy alone who may benefit from targeted therapy.

Sign in / Sign up

Export Citation Format

Share Document